News
BFRI
0.9455
-7.30%
-0.0745
Weekly Report: what happened at BFRI last week (0622-0626)?
Weekly Report · 1d ago
Weekly Report: what happened at BFRI last week (0615-0619)?
Weekly Report · 06/22 10:40
Biofrontera Shareholders Approve Director Elections and Equity Plan
TipRanks · 06/17 21:29
Biofrontera shareholders approve amended 2021 omnibus incentive plan share increase to 8,750,000
PUBT · 06/17 20:06
Weekly Report: what happened at BFRI last week (0608-0612)?
Weekly Report · 06/15 10:40
Weekly Report: what happened at BFRI last week (0601-0605)?
Weekly Report · 06/08 10:35
Biofrontera Earnings Call Highlights Growth And Risks
TipRanks · 06/03 00:15
Weekly Report: what happened at BFRI last week (0525-0529)?
Weekly Report · 06/01 10:41
Biofrontera FY26 Q1 pretax profit more than doubles to EUR 2.2 million
PUBT · 05/29 22:12
Weekly Report: what happened at BFRI last week (0518-0522)?
Weekly Report · 05/25 10:45
Biofrontera participates in Lytham Partners Spring 2026 Investor Conference webcast
PUBT · 05/21 13:16
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Barchart · 05/21 08:15
This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Benzinga · 05/19 14:34
This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday
Benzinga · 05/19 14:32
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
TipRanks · 05/19 13:35
Biofrontera Price Target Maintained With a $3.00/Share by Benchmark
Dow Jones · 05/19 12:51
Biofrontera Cut to Speculative Buy From Buy by Benchmark
Dow Jones · 05/19 12:51
Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3
Benzinga · 05/19 12:41
BIOFRONTERA INC <BFRI.O>: BENCHMARK CUTS TO SPECULATIVE BUY FROM BUY
Reuters · 05/19 10:53
Biofrontera downgraded to Speculative Buy from Buy at Benchmark
TipRanks · 05/19 10:15
More
Webull provides a variety of real-time BFRI stock news. You can receive the latest news about Biofrontera Inc through multiple platforms. This information may help you make smarter investment decisions.
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.